RSS
Brazil offers pharma large, growing market
Scott Sonnenblick, partner at Linklaters LLP
"The interest in Brazil goes across all segments in the pharma industry, large and small," says Linklaters LLP partner Scott Sonnenblick. Brazil provides "access to a good research capability, access to a large market and access to a country that is growing rapidly," he explains. No wonder Amgen Inc. is buying São Paulo-based oncology drugmaker Bergamo for $215 million and reacquiring the Brazilian rights to products from Hypermarcas SA. The Deal magazine's David Holley spoke with Sonnenblick as part of our Emerging Markets Outlook video series, sponsored by Merrill DataSite. - Mary Kathleen Flynn
